Lyka Labs Q1 loss Rs 30 cr standalone, to divest Lyka BDR subsidiary
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lyka Labs posted Q1 FY27 standalone net loss of Rs 29.77 cr versus profit of Rs 2.10 cr a year ago. Revenue fell sharply to Rs 28.54 cr from Rs 124.88 cr, hurt by exceptional items of Rs 29.90 cr. Consolidated net loss was Rs 8.07 cr. Board approved 100 percent divestment of subsidiary Lyka BDR International, which has negative net worth of Rs 4.49 cr. Results are restated after merger of Lyka Export into the company. Auditor gave an unqualified review report.
Weak quarter with steep revenue fall and large loss; divesting loss-making subsidiary may help streamline operations ahead.